{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:24:15Z","timestamp":1747207455606,"version":"3.40.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHAMC"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The major physiopathological mechanism underlying Acute Coronary Syndromes (ACS)\nis atherosclerotic plaque rupture with resultant coronary thrombosis, posing a big burden in\nhealth care systems. Dual anti-platelet therapy (DAPT) can improve CV outcome with a prolonged\nregimen, albeit at the cost of increased bleeding rates. We performed a narrative literature review\non the topic, in which we explored databases through April 15th, 2020, with no restrictions on language.\nKeywords related to antiplatelet therapy, P2Y12 inhibitor, aspirin and DAPT were utilized.\nRandomized clinical trials, large prospective studies, systematic reviews and meta-analysis were included.\nWe hand-searched the reference lists of included articles and relevant reviews. The review\nrevealed that when choosing antiplatelet agents, the decision should be driven by pharmacodynamic\nproperties as well as demonstrated efficacy and safety. Additionally, it was noted that in patients\nundergoing percutaneous coronary intervention, prasugrel and ticagrelor are preferred. In patients\nwith a high risk of bleeds or receiving thrombolysis, or when cost or specific patient issues exist,\nclopidogrel is considered though it is a second-line therapy. Due to an elevated risk of bleeds, triple\ntherapy should be avoided, as evidence shows effectiveness and safety with regimens without\nASA. Furthermore, multiple studies have also shown that regimens shorter than 12 months of\nDAPT could be adequate for many patients, and newer guidelines are likely to reflect it. There are\nspecific recommendations for switching among antiplatelets, mostly based on registries and pharmacodynamic\nstudies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871525718666201207201552","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T19:16:08Z","timestamp":1607454968000},"page":"187-200","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic \/ Antiplatelet Therapy in Patients with Stable Coronary Artery Disease and After Acute Coronary Syndrome"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-6141","authenticated-orcid":true,"given":"Jose B.","family":"Cruz Rodriguez","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Diseases, Texas Tech University Health Science Center El Paso, El Paso, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-6049","authenticated-orcid":true,"given":"Kunal","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Science Center El Paso, El Paso, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-8692","authenticated-orcid":true,"given":"Tariq","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Diseases, Texas Tech University Health Science Center El Paso, El Paso, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Cardiovascular &amp; Hematological Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/188796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188796\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/188796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T14:42:14Z","timestamp":1637160134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188796\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871525718666201207201552","relation":{},"ISSN":["1871-5257"],"issn-type":[{"type":"print","value":"1871-5257"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}